Developing EZH2-Targeted Therapy for Lung Cancer

Targeted therapy for lung cancer.

To meet that challenge, an action plan [2] was designed by the European Respiratory Society (ERS) Thoracic Oncology Assembly officers in March 2010, which was subsequently approved and strongly welcomed by the ERS Executive Committee. Today the Thoracic Oncology Assembly has almost achieved all of the following. 1) To create a Task Force for a European initiative for quality management in lung ...

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

UNLABELLED As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non-small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive. Here, we demonstrate t...

Targeted cancer therapy: review article

Cancer is one of the most dangerous health problems of today modern societies which has an increasing rate especially in developing countries. There are many diverse ongoing treatment attempts trying to defeat cancer. Despite that, scientists have been unable to find a permanent cure for this disease. In many cases although there is a successful first response in patients, cancer cells are fina...

Personalized Targeted Therapy for Lung Cancer

Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical characterizations, prognosis, response and tolerance to treatment. Personalized medicine refers to the use of markers to predict which patient will most likely benefit from a treatment. In lung cancer, the well-developed epidermal growth factor recept...

Cancer. A bull's eye for targeted lung cancer therapy.